Skip to main content
Top
Published in: European Journal of Clinical Microbiology & Infectious Diseases 7/2004

01-07-2004 | Brief Report

Isolated subcutaneous cryptococcal abscess after a BEACOPP regimen for Hodgkin’s lymphoma

Authors: L. Rosset, M. Toetsch, L. Kaiser, C. Helg

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 7/2004

Login to get access

Excerpt

A 16-year-old girl from Kenya presented in March 2002 with weight loss, fatigue, night sweats, backache, and a left-sided limping gait of 4 months’ duration. Radiological investigations included computed tomography scans of the chest and abdomen, which showed large mediastinal, retroperitoneal and hilar lymphadenopathy, pulmonary infiltrates, and hepatosplenomegaly. Magnetic resonance imaging of the spine revealed an infiltration of the third lumbar vertebra with involvement of the posterior wall. Laboratory evaluation revealed discrete leukopenia of 3.5 g/l with a normal differential leukocyte count. HIV serology was negative. A cervical adenopathy biopsy was positive for mixed cellularity Hodgkin’s disease (HD), and a bone marrow biopsy showed diffuse infiltration with Hodgkin cells. On the basis of these findings, the diagnosis of advanced stage IVB HD was made in accordance with the Ann Harbor lymphoma classification system. …
Literature
1.
go back to reference Engel C, Loeffler M, Schmitz S, Tesch H, Diehl V (2000) Acute haematological toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin’s disease. Ann Oncol 11:1105–1114 Engel C, Loeffler M, Schmitz S, Tesch H, Diehl V (2000) Acute haematological toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin’s disease. Ann Oncol 11:1105–1114
2.
go back to reference Korfel A, Messen HD, Schwarz S, Thiel E (1998) Cryptococcosis in Hodgkin’s disease: description of two cases and review of the literature. Ann Hematol 76:283–286CrossRefPubMed Korfel A, Messen HD, Schwarz S, Thiel E (1998) Cryptococcosis in Hodgkin’s disease: description of two cases and review of the literature. Ann Hematol 76:283–286CrossRefPubMed
3.
go back to reference Dimino-Emme L, Gurevich AW (1995) Cutaneous manifestations of disseminated cryptococcosis. J Am Acad Dermatol 32:844–850PubMed Dimino-Emme L, Gurevich AW (1995) Cutaneous manifestations of disseminated cryptococcosis. J Am Acad Dermatol 32:844–850PubMed
4.
go back to reference Blanco P, Viallard JF, Beylot-Barry M, Faure I, Mercier P, Vergier B, Pellegrin JL, Leng B (1999) Cutaneous cryptococcosis resembling molluscum contagiosum in a patient with non-Hodgkin’s lymphoma. Clin Infect Dis 29:683–684PubMed Blanco P, Viallard JF, Beylot-Barry M, Faure I, Mercier P, Vergier B, Pellegrin JL, Leng B (1999) Cutaneous cryptococcosis resembling molluscum contagiosum in a patient with non-Hodgkin’s lymphoma. Clin Infect Dis 29:683–684PubMed
5.
go back to reference Romano C, Taddeucci P, Miracco D, Massai L (2001) Primary cutaneous cryptococcosis due to Cryptococcus neoformans in a woman with non-Hodgkin’s lymphoma. Acta Derm Venereol 81:220–221CrossRefPubMed Romano C, Taddeucci P, Miracco D, Massai L (2001) Primary cutaneous cryptococcosis due to Cryptococcus neoformans in a woman with non-Hodgkin’s lymphoma. Acta Derm Venereol 81:220–221CrossRefPubMed
6.
go back to reference Noble RC, Faardo LF (1972) Primary cutaneous cryptococcosis: review and morphologic study. Am J Clin Pathol 57:13–22PubMed Noble RC, Faardo LF (1972) Primary cutaneous cryptococcosis: review and morphologic study. Am J Clin Pathol 57:13–22PubMed
7.
go back to reference Vigouroux S, Morin O, Milpied N, Mahé B, Rapp MJ, Harousseau JL (2000) Infections à Cryptococcus neoformans dans les hémopathies malignes. Rev Med Interne 21:955–960CrossRefPubMed Vigouroux S, Morin O, Milpied N, Mahé B, Rapp MJ, Harousseau JL (2000) Infections à Cryptococcus neoformans dans les hémopathies malignes. Rev Med Interne 21:955–960CrossRefPubMed
8.
go back to reference Ng WF, Loo KT (1993) Cutaneous cryptococcosis—primary versus secondary disease. Am J Dermatopathol 15:372–377PubMed Ng WF, Loo KT (1993) Cutaneous cryptococcosis—primary versus secondary disease. Am J Dermatopathol 15:372–377PubMed
9.
go back to reference Powderly WG et al (1995) A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med 332:700–705CrossRefPubMed Powderly WG et al (1995) A randomized trial comparing fluconazole with clotrimazole troches for the prevention of fungal infections in patients with advanced human immunodeficiency virus infection. N Engl J Med 332:700–705CrossRefPubMed
10.
go back to reference Prentice HG, Kibbler CC, Prentice AG (2003) Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol 110:273–284CrossRef Prentice HG, Kibbler CC, Prentice AG (2003) Towards a targeted, risk-based, antifungal strategy in neutropenic patients. Br J Haematol 110:273–284CrossRef
Metadata
Title
Isolated subcutaneous cryptococcal abscess after a BEACOPP regimen for Hodgkin’s lymphoma
Authors
L. Rosset
M. Toetsch
L. Kaiser
C. Helg
Publication date
01-07-2004
Publisher
Springer-Verlag
Published in
European Journal of Clinical Microbiology & Infectious Diseases / Issue 7/2004
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI
https://doi.org/10.1007/s10096-004-1157-x

Other articles of this Issue 7/2004

European Journal of Clinical Microbiology & Infectious Diseases 7/2004 Go to the issue

Announcements

July 2004

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine